<DOC>
	<DOCNO>NCT00160732</DOCNO>
	<brief_summary>The purpose study determine safety transplant human islet cell control hyperglycemia brittle and/or complex patient type 1 diabetes . In addition , initial observation make regard effectiveness reverse hypoglycemia treatment . The `` Edmonton Protocol '' use specific anti-rejection drug without steroid also evaluate .</brief_summary>
	<brief_title>Allogenic Islet Cell Transplantation</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<criteria>Patients must type I diabetes mellitus , document undetectable Cpeptide . Patients must diabetic least five year , age 18 58 year . Patients must intensive regimen glucose monitor exogenous insulin injection ( define great equal three check injection per day ) . This regimen must prescribe supervised patient 's diabetologist . Despite intensive therapy , patient must least one follow : Brittle diabetes ( metabolic instability ) , define elevate mean amplitude glycemic excursion ; Hypoglycemic unawareness , least one episode past two year hypoglycemia require assistance another person ( e.g. , family member , emergency medical technician [ EMT ] , etc . ) , associate fingerstick blood glucose ( FSBG ) &lt; 50 mg/dl prompt recovery administration oral glucose , intravenous glucose , glucagon ; Progressive complication diabetes ( nephropathy manifest proteinuria , retinopathy document ophthalmologist dilate eye exam , neuropathy determine neurologist ) . Patients must able give informed consent . Failure meet inclusion criterion Panel Reactive Antibody ( PRA ) &gt; 10 % Creatinine clearance &lt; 80 mL/min Prior organ transplant Portal hypertension : refers portal hypertension diagnose previously mean , , investigator ' evaluation , symptom and/or sign liver dysfunction without portal hypertension include , limited , jaundice , ascites , encephalopathy , spider angioma , coagulopathy , periumbilical venous engorgement . Elevated portal pressure , measure intended islet infusion , may also result discontinuation infusion . Abnormal liver function test ( &gt; 2 time upper limit normal defined University Chicago Clinical Laboratory ) History malignancy . Any history malignancy patient `` adequate '' period evidence neoplastic disease rule individual enrol study . Rather , preenrollment screening malignancy follow current establish guideline solidorgan transplant . These current guideline appear Kasiske , B.L. , et al . `` The Evaluation Renal Transplant Candidates : Clinical Practice Guidelines , '' American Journal Transplantation 1 ( Supplement 2 ) : 1222 , 2001 . Active peptic ulcer disease Pregnancy , inability comply contraceptive regimen Severe unremitting gastroparesis diarrhea Active infection Serologic positivity HIV and/or hepatitis Chest radiographic abnormality consistent neoplastic infectious disease Major ongoing psychiatric illness and/or substance abuse Noncompliance current medical regimen Obesity ( body mass index [ BMI ] &gt; 28 ) Any medical condition preclude safe transplantation immunosuppression Ejection fraction &lt; 30 % Myocardial infarction ( MI ) within past 6 month Known allergy hypersensitivity immunosuppressive agent use protocol Inability provide write informed consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>58 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Islet Cell Transplant</keyword>
	<keyword>Human islet cell infusion</keyword>
	<keyword>Juvenile-onset diabetes</keyword>
</DOC>